Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral Sclerosis

Trial Profile

A Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral Sclerosis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dextran sulfate (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors TikoMed
  • Most Recent Events

    • 16 Sep 2019 Status changed from recruiting to discontinued.
    • 02 Nov 2018 According to a TikoMed media release, first patient has been treated in the trial.
    • 14 Aug 2018 According to a TikoMed media release, this study is performed at and in collaboration with Sahlgrenska University Hospital, Gothenburg, Sweden. Assoc. Professor Lennart Persson, an expert in ALS, will be principal investigator.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top